Coloplast A/S (OTCMKTS:CLPBY) Rating Increased to Moderate Buy at Royal Bank of Canada

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by Royal Bank of Canada from a “hold” rating to a “moderate buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the company. Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th. Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 11th.

Coloplast A/S Price Performance

CLPBY opened at $11.10 on Monday. Coloplast A/S has a 1 year low of $10.54 and a 1 year high of $14.34. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The firm’s fifty day moving average price is $11.11 and its two-hundred day moving average price is $12.26.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01). Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. On average, equities analysts anticipate that Coloplast A/S will post 0.31 EPS for the current year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.